Brainstorm Cell Therapeutics (BCLI) Earning Somewhat Positive News Coverage, Study Finds

News headlines about Brainstorm Cell Therapeutics (NASDAQ:BCLI) have been trending somewhat positive on Tuesday, according to Accern Sentiment. Accern rates the sentiment of news coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Brainstorm Cell Therapeutics earned a media sentiment score of 0.19 on Accern’s scale. Accern also gave news coverage about the biotechnology company an impact score of 45.3003379552869 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the next few days.

Here are some of the media stories that may have impacted Accern’s analysis:

BCLI has been the topic of several recent analyst reports. ValuEngine raised Brainstorm Cell Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Maxim Group set a $9.00 price objective on Brainstorm Cell Therapeutics and gave the company a “buy” rating in a report on Wednesday, December 27th.

Shares of Brainstorm Cell Therapeutics (NASDAQ:BCLI) traded down $0.07 during mid-day trading on Tuesday, hitting $3.57. The stock had a trading volume of 41,800 shares, compared to its average volume of 125,267. The firm has a market capitalization of $67.27, a price-to-earnings ratio of -11.16 and a beta of 2.21. Brainstorm Cell Therapeutics has a fifty-two week low of $2.57 and a fifty-two week high of $5.18.

Brainstorm Cell Therapeutics (NASDAQ:BCLI) last announced its quarterly earnings data on Tuesday, October 17th. The biotechnology company reported ($0.13) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.16) by $0.03. During the same period last year, the business earned ($0.09) earnings per share. research analysts predict that Brainstorm Cell Therapeutics will post -0.37 earnings per share for the current year.

TRADEMARK VIOLATION WARNING: “Brainstorm Cell Therapeutics (BCLI) Earning Somewhat Positive News Coverage, Study Finds” was originally published by StockNewsTimes and is the property of of StockNewsTimes. If you are viewing this news story on another domain, it was illegally copied and republished in violation of U.S. and international copyright & trademark laws. The legal version of this news story can be accessed at https://stocknewstimes.com/2018/01/16/somewhat-favorable-media-coverage-somewhat-unlikely-to-affect-brainstorm-cell-therapeutics-bcli-share-price.html.

Brainstorm Cell Therapeutics Company Profile

Brainstorm Cell Therapeutics Inc is a biotechnology company. The Company is engaged in developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig’s disease), Multiple Sclerosis (MS) and Parkinson’s disease (PD), among others.

Insider Buying and Selling by Quarter for Brainstorm Cell Therapeutics (NASDAQ:BCLI)

Receive News & Ratings for Brainstorm Cell Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brainstorm Cell Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply